

Learner Notification

MED Learning Group

Identifying Appropriate High-Risk Patients and Managing Drug-Drug Interactions with Outpatient Antiviral Therapy: Assessing Current Best Practices in 2023 Module 1

May 19, 2023 – May 19, 2024

Online

Acknowledgement of Financial Commercial Support

Pfizer

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 0.50 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Evaluate current guidelines recommendations in the identification of COVID-19 infections to inform the use of outpatient therapy in patients at high risk of severe consequences of COVID-19.
2. Summarize the latest updates in selection of patients for outpatient therapy in consideration of appropriate monitoring parameters, drug-disease interactions, and drug-drug interactions.
3. Interpret current guidelines for management of drug-drug interactions with outpatient therapy in non-hospitalized patients at high risk of serious consequences of COVID-19 infection.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1--6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Timothy	Albertson	Johnson and Johnson: Consultant
Russie	Allen	NA
Rashado	Coote	NA
Lisa	Crenshaw	NA
Matthew	Frese	NA
Christina	Gallo	NA
Debra	Gordon	NA
Teresa L.	Keating	NA
Morgan	Kravarik	NA
Jo	Shultz	NA

Lauren	Welch	NA
--------	-------	----

Questions? Email Certificate@AmedcoEmail.com